Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open-Label Single-Arm Trial of the Efficacy and Safety of BCD-100 in Combination With Platinum-Based Chemotherapy and Bevacizumab as First Line Treatment in Patients With Recurrent, Persistent or Metastatic Cervical Cancer

NCT03912402 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT03912402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03912402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open-Label Single-Arm Trial of the Efficacy and Safety of BCD-100 in Combination With Platinum-Based Chemotherapy and Bevacizumab as First Line Treatment in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Lead sponsor
Biocad
Phase
Phase 2
Overall status
Unknown status
Start date
December 25, 2018
Completion date
July 7, 2020
Enrollment
49 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cervical cancer metastatic, cervical cancer recurrent